Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development SummitBusiness Wire • 10/26/21
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific JournalBenzinga • 10/21/21
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal.Business Wire • 10/21/21
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021Business Wire • 10/05/21
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/09/21
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical UpdateBusiness Wire • 08/26/21
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite BoardBusiness Wire • 08/05/21
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for PetsBusiness Wire • 06/28/21
CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTSBenzinga • 06/03/21
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate NamodenosonBusiness Wire • 06/02/21
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021Business Wire • 06/02/21
CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTSBenzinga • 05/27/21
Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical UpdateBusiness Wire • 05/27/21
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®Business Wire • 05/27/21
CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATESBenzinga • 05/12/21
Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021Business Wire • 04/29/21
